Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 231.13% from the stock’s current price.

Kiora Pharmaceuticals Stock Up 1.0 %

Shares of KPRX opened at $3.02 on Friday. Kiora Pharmaceuticals has a 52-week low of $2.91 and a 52-week high of $6.48. The stock has a fifty day simple moving average of $3.48 and a two-hundred day simple moving average of $3.48. The company has a market capitalization of $9.06 million, a PE ratio of 2.90 and a beta of -0.46.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Tuesday, March 25th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.40). The business had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.75 million. As a group, equities analysts anticipate that Kiora Pharmaceuticals will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC grew its holdings in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent reporting period. 76.97% of the stock is owned by hedge funds and other institutional investors.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.